Hyperlipoproteinemia causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
| Line 125: | Line 125: | ||
====High HDL Causes==== | ====High HDL Causes==== | ||
{{col-begin|width=80%}} | |||
{{col-break|width=33%}} | |||
*[[Aerobic exercise]] | |||
*[[Anacetrapib]] | |||
*[[Anorexia nervosa]] | |||
*[[ApoA-1 Milano]] | |||
*[[Lipoma|Benign symmetrical lipomatosis]] | |||
*[[Cannabis]] | |||
*[[Caprylic acid]] | |||
*[[CHI-SQUARE Study|CER-001]] | |||
*[[Cholesterylester transfer protein|Cholesteryl ester transfer protein (CETP) deficiency]] | |||
*[[CSL-112 Trial - Phase 1|CSL-112]] | |||
*[[Dalcetrapib]] | |||
*[[Decanoic acid]] | |||
*[[Dietary fiber]] | |||
*[[Doxazosin]] | |||
*[[Estrogen]] | |||
*[[Weight loss|Excessive weight loss]] | |||
{{col-break|width=33%}} | |||
*[[Hepatic lipase|Familial hyperalphalipoproteinemia or hepatic lipase deficiency]] | |||
*[[Fibrates]] | |||
*[[Hexanoic acid]] | |||
*[[Lauric acid]] | |||
*[[Liver cirrhosis]] | |||
*[[Lovaza]] | |||
*[[Magnesium]] | |||
*[[Alcohol and cardiovascular disease#Possible Mechanisms of Benefits|Moderate alcohol consumption]] | |||
*[[Niacin]] | |||
*[[Omega-3 fatty acid]] | |||
*[[Prazosin]] | |||
*[[Primary biliary cirrhosis]] | |||
*[[Smoking cessation]] | |||
*[[Statins]] | |||
*[[Torcetrapib]] | |||
*[[Unsaturated fat]] | |||
{{col-end}} | |||
====High IDL Causes==== | ====High IDL Causes==== | ||
Revision as of 21:10, 13 November 2013
|
Hyperlipoproteinemia Microchapters |
|
ACC/AHA Guideline Recommendations |
|
Intensity of statin therapy in primary and secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]
Overview
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Causes based on Major Lipoprotein Detected in Blood Laboratory Test
High Chylomicron Causes
High Chylomicron Remnant Causes
High HDL Causes
High IDL Causes
High LDL Causes
High VLDL Causes
High Total Cholesterol Causes
High Triglyceride Causes
Combined List of Causes in Alphabetical Order
References
- ↑ Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995). "Effects of antihypertensive therapy on serum lipids". Ann Intern Med. 122 (2): 133–41. PMID 7992988.
- ↑ Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE; et al. (2003). "Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis". Ann Rheum Dis. 62 (9): 842–5. PMC 1754645. PMID 12922956.
- ↑ Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter
|month=ignored (help) - ↑ Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH; et al. (1992). "Familial lipoprotein disorders in patients with premature coronary artery disease". Circulation. 85 (6): 2025–33. PMID 1534286.
- ↑ Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Yoshimura, T.; Ito, M.; Sakoda, Y.; Kobori, S.; Okamura, H. (1998). "Rare case of autoimmune hyperchylomicronemia during pregnancy". Eur J Obstet Gynecol Reprod Biol. 76 (1): 49–51. PMID 9481547. Unknown parameter
|month=ignored (help) - ↑ Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S; et al. (1992). "Severe defect in clearing postprandial chylomicron remnants in dialysis patients". Kidney Int. 42 (5): 1247–52. PMID 1453610.
- ↑ Ito M, Takamatsu J, Matsuo T, Kameoka K, Kubota S, Fukata S; et al. (2003). "Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement". Clin Endocrinol (Oxf). 58 (5): 621–6. PMID 12699445.
- ↑ Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS; et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis. 187 (1): 116–22. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.
- ↑ Brasaemle DL, Cornely-Moss K, Bensadoun A (1993). "Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E." J Lipid Res. 34 (3): 455–65. PMID 8468529.